semaglutide ban Fifth Circuit probes FDA on compounded GLP-1s why is semaglutide being banned

This study aims to investigate whether semaglutide can reduce the progression of noncalcified coronary atherosclerotic plaque volume, as measured by serial coronary computed tomography angiography (CTA), over a one-year period compared to a placebo, in individuals with diabetes

Among these participants, 48.7% achieved at least 20% weight reduction versus 3.1% on placebo

However, interpretation of these signatures may be confounded by kidney function and medication use, and clinical translation will require rigorous external validation, particularly in prospective cohorts and trials specifically designed for DKD

The triple-receptor mechanism produces stronger metabolic effects than dual or single agonists in head-to-head research data